Redwood Pharma AB
Redwood Pharma AB engages in the development of ophthalmic drugs for medical needs in Sweden. Its lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women; and RP501, a next generation smart hydrogel medical device for the treatment of mild dry eye. The company was founded in 2012 and is headquartered in Stockholm, Sweden.
Redwood Pharma AB (REDW) - Total Liabilities
Latest total liabilities as of March 2024: Skr1.49 Million SEK
Based on the latest financial reports, Redwood Pharma AB (REDW) has total liabilities worth Skr1.49 Million SEK as of March 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Redwood Pharma AB - Total Liabilities Trend (2014–2023)
This chart illustrates how Redwood Pharma AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Redwood Pharma AB Competitors by Total Liabilities
The table below lists competitors of Redwood Pharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trendline
TA:TREN
|
Israel | ILA43.35 Million |
|
Synel M.L.L Payway Ltd
TA:SNEL
|
Israel | ILA61.15 Million |
|
STATOIL
MU:DNQ
|
Germany | €90.73 Billion |
|
NATIONAL AUSTRAL BK
MU:NAL
|
Germany | €1.02 Trillion |
|
OSAKA GAS
BE:OSA
|
Germany | €1.48 Trillion |
|
DOUGLAS DYNAMICS
BE:5D4
|
Germany | €404.83 Million |
Liability Composition Analysis (2014–2023)
This chart breaks down Redwood Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Redwood Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Redwood Pharma AB (2014–2023)
The table below shows the annual total liabilities of Redwood Pharma AB from 2014 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | Skr893.88K | -69.31% |
| 2022-12-31 | Skr2.91 Million | -45.28% |
| 2021-12-31 | Skr5.32 Million | -7.70% |
| 2020-12-31 | Skr5.77 Million | +154.38% |
| 2019-12-31 | Skr2.27 Million | -44.76% |
| 2018-12-31 | Skr4.10 Million | -34.49% |
| 2017-12-31 | Skr6.26 Million | +203.61% |
| 2016-12-31 | Skr2.06 Million | +391.16% |
| 2015-12-31 | Skr420.10K | +1453.00% |
| 2014-12-31 | Skr27.05K | -- |